Search Results - "Long, GV"

Dabrafenib and its potential for the treatment of metastatic melanoma by Menzies, Alexander M, Long, Georgina V, Murali, Rajmohan

“…The purpose of this study is to review the development of BRAF inhibitors, with emphasis on the trials conducted with dabrafenib (GSK2118436) and the evolving…”
Get full text

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma by Tawbi, Hussein A, Schadendorf, Dirk, Lipson, Evan J, Ascierto, Paolo A, Matamala, Luis, Castillo Gutiérrez, Erika, Rutkowski, Piotr, Gogas, Helen J, Lao, Christopher D, De Menezes, Juliana Janoski, Dalle, Stéphane, Arance, Ana, Grob, Jean-Jacques, Srivastava, Shivani, Abaskharoun, Mena, Hamilton, Melissa, Keidel, Sarah, Simonsen, Katy L, Sobiesk, Anne Marie, Li, Bin, Hodi, F. Stephen, Long, Georgina V

“…Two defined immune checkpoints have been exploited for cancer treatment. LAG-3 is a third immune checkpoint that blocks lymphocyte activation. Relatlimab, a…”
Get full text

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study by Long, G.V., Flaherty, K.T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalà, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J.B.A.G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M.A., Lane, S.R., Legos, J.J., Mookerjee, B., Grob, J.-J.

“…Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall survival (OS) with combination dabrafenib and…”
Get full text

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials by Versluis, J.M., Menzies, A.M., Sikorska, K., Rozeman, E.A., Saw, R.P.M., van Houdt, W.J., Eriksson, H., Klop, W.M.C., Ch’ng, S., van Thienen, J.V., Mallo, H., Gonzalez, M., Torres Acosta, A., Grijpink-Ongering, L.G., van der Wal, A., Bruining, A., van de Wiel, B.A., Scolyer, R.A., Haanen, J.B.A.G., Schumacher, T.N., van Akkooi, A.C.J., Long, G.V., Blank, C.U.

“…Neoadjuvant ipilimumab plus nivolumab has yielded high response rates in patients with macroscopic stage III melanoma. These response rates translated to high…”
Get full text

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy by Owen, C.N., Shoushtari, A.N., Chauhan, D., Palmieri, D.J., Lee, B., Rohaan, M.W., Mangana, J., Atkinson, V., Zaman, F., Young, A., Hoeller, C., Hersey, P., Dummer, R., Khattak, M.A., Millward, M., Patel, S.P., Haydon, A., Johnson, D.B., Lo, S., Blank, C.U., Sandhu, S., Carlino, M.S., Larkin, J.M.G., Menzies, A.M., Long, G.V.

“…Anti-programmed cell death protein 1 (PD-1) antibodies (PD1) prolong recurrence-free survival in high-risk resected melanoma; however, approximately 25%–30% of…”
Get full text

Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study) by Mandalà, Mario, Ferrari, Andrea, Brecht, Ines B., Suijkerbuijk, Karijn PM, Maschke, Linda, Giannarelli, Diana, Indini, Alice, Ubaldi, Martina, Pecci, Giulia, Atkinson, Victoria, Helgadottir, Hildur, Chiaravalli, Stefano, Benannoune, Naima, Robert, Caroline, Teterycz, Pawel, Rutkowski, Piotr, Puig, Susana, Madonna, Gabriele, Kebudi, Rejin, Grynberg, Shirly, Arantes, Lidia MRB, Bien, Ewa, Krawczyk, Malgorzata, Pasquale, Maria Debora De, Dierselhuis, Miranda P., Massi, Daniela, Long, Georgina V., Ascierto, Paolo Antonio, Eggermont, Alexander M.M.

“…Data on the efficacy and safety of anti PD-1 antibodies in children and adolescents (CA) with melanoma are lacking. The aim of this study was to determine…”
Get full text

The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo by Reijers, Irene L.M., Menzies, Alexander M., Versluis, Judith M., Saw, Robyn P.M., van Houdt, Winan J., Kapiteijn, Ellen, Van Der Veldt, Astrid Aplonia Maria, Suijkerbuijk, Karijn, Eriksson, Hanna, Hospers, Geke, Klop, Willem M.C., Lopez-Yurda, Marta I., Grijpink-Ongering, Lindsay G., Gonzalez, Maria, Spillane, Andrew John, Scolyer, Richard A., van de Wiel, Bart A., Van Akkooi, Alexander Christopher Jonathan, Long, Georgina V., Blank, Christian U.

“…101 Background: Neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) has been shown to induce high pathologic response rates associated with an excellent…”
Get full text

Sentinel lymph node biopsy rates in Victoria, 2018 and 2019 by Watts, Caroline, Spillane, Andrew, Henderson, Michael A, Cust, Anne, Braithwaite, J, Gyorki, DE, Hong, AM, Kelly, JW, Long, GV, Mar, VJ, Menzies, AM, Morton, RL, Rapport, F, Saw, RPM, Schmid, H, Scolyer, RA, Smith, AL, Winder, A, Mann, GJ

Get full text

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study by Long, G.V., Flaherty, K.T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalá, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J.B.A.G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M.A., Lane, S.R., Legos, J.J., Mookerjee, B., Grob, J.-J.

Get full text

The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases: A multicenter cohort study by Olofsson Bagge, Roger, Holmberg, Carl Jacob, Hieken, Tina J., Zager, Jonathan S., Long, Georgina V., Van Akkooi, Alexander Christopher Jonathan, Karakousis, Giorgos C, Pallan, Lalit, Vetto, John T., Gyorki, David E., Ascierto, Paolo Antonio, Dummer, Reinhard, Hui, Jane Yuet Ching, Schachter, Jacob, Helgadottir, Hildur, Kroon, Hidde, Rothermel, Luke Daniel, Carlino, Matteo S., Broman, Kristy Kummerow, Ny, Lars

“…9569 Background: Guidelines addressing melanoma in-transit metastasis (ITM) recommend immune checkpoint inhibitors (ICI) as a first-line treatment option,…”
Get full text

Twenty-four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma by Rozeman, Elisa A., Reijers, Irene L.M., Hoefsmit, Esmée P, Sikorska, Karolina, Krijgsman, Oscar, Van De Wiel, Bart A., Dimitriadis, Petros, Eriksson, Hanna, Gonzalez, Maria, Grijpink-Ongering, Lindsay G, Kerkhoven, Ron M., Broeks, Annegien, Klop, Willem M.C., Spillane, Andrew, Saw, Robyn PM, Van Akkooi, Alexander Christopher Jonathan, Scolyer, Richard A., Menzies, Alexander M., Long, Georgina V., Blank, Christian U.

“…Abstract only 10015 Background: Early results of the OpACIN-neo study testing 3 different dosing schedules of neoadjuvant IPI + NIVO demonstrated that 2 cycles…”
Get full text

Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase II OpACIN-neo trial by Reijers, I.L.M., Rozeman, E.A., Menzies, A.M., Versluis, J.M., van de Wiel, B.A., Sikorska, K., Eriksson, H., Shannon, K., Bierman, C., van Tinteren, H., Gonzalez, M., Spillane, A.J., Saw, R.P., Scolyer, R.A., van Akkooi, A.C.J., Hansson, J., Long, G.V., Blank, C.U.

Get full text

Preliminary findings from part 1 of COMBI-i: A phase III study of anti–PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma by Dummer, Reinhard, Arance Fernández, Ana María, Hansson, Johan, Larkin, James M. G., Long, Georgina V., Gasal, Eduard, Kaper, Mathilde, Upalawanna, Allison, Mookerjee, Bijoyesh, Atkinson, Victoria

“…Abstract only 189 Background: Checkpoint inhibitors and targeted therapies have improved outcomes in pts with advanced BRAF V600–mutant melanoma; however, many…”
Get full text

OpACIN-neo: A multicenter phase II study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) by Blank, C.U., Rozeman, E.A., Menzies, A.M., van de Wiel, B.A., Adhikari, C., Sikorska, K., Krijgsman, O., Eriksson, H., Bierman, C., Grijpink-Ongering, L., Gonzalez, M., Broeks, A., Guminski, A.D., Spillane, A.J., Klop, W.M.C., Saw, R.P.M., Scolyer, R.A., van Akkooi, A.C.J., Hansson, J., Long, G.V.

Get full text

Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo) by Rozeman, Elisa A., Van Akkooi, Alexander Christopher Jonathan, Menzies, Alexander M., Smith, Myles, Scolyer, Richard A., Pronk, Loes M., Gonzales, Maria, Hoeller, Christoph, Hansson, Johan, Larkin, James M. G., Long, Georgina V., Blank, Christian U.

“…Abstract only…”
Get full text

Knowledge and attitudes of Australian dermatologists towards sentinel lymph node biopsy for melanoma: a mixed methods study by Smith, Andrea L, Watts, Caroline G, Robinson, Samuel, Schmid, Helen, Goumas, Chris, Mar, Victoria J, Thompson, John F, Rapport, Frances, Cust, Anne E, Braithwaite, J, Gyorki, DE, Henderson, M, Hong, AM, Kelly, JW, Long, GV, Menzies, AM, Morton, RL, Saw, RPM, Scolyer, RA, Spillane, AJ, Mann, GJ

“…Background/Objectives In melanoma management, sentinel lymph node biopsy (SLNB) is used to stage patients and to indicate prognosis. More recently, it has been…”
Get full text

Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial by Reijers, Irene, Rozeman, Elisa A., Menzies, Alexander M., Van De Wiel, Bart A., Eriksson, Hanna, Suijkerbuijk, Karijn, Van Der Veldt, Astrid Aplonia Maria, Kapiteijn, Ellen, Hospers, Geke, Klop, Willem M.C., Spillane, Andrew, Scolyer, Richard A., Svane, Inge Marie, Bastholt, Lars, Schmidt, Henrik, Larkin, James M.G., Van Akkooi, Alexander Christopher Jonathan, Long, Georgina V., Blank, Christian U.

“…Abstract only TPS9605 Background: Adjuvant (adj) immune checkpoint inhibition (ICI) improves relapse free survival (RFS) in stage III melanoma patients (pts)…”
Get full text

Advanced cancer patients’ attitudes towards, and experiences with, screening for somatic mutations in tumours: a qualitative study by Liang, R., Meiser, B., Smith, S., Kasparian, N.A., Lewis, C.R., Chin, M., Long, G.V., Ward, R., Menzies, A.M., Harris‐Wai, J.N., Kaur, R.

“…Somatic mutations in key oncogenes in non‐small cell lung cancer (NSCLC) and melanoma are important determinants of tumour sensitivity to targeted therapies…”
Get full text

Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo) by Rozeman, Elisa A., Van Akkooi, Alexander Christopher Jonathan, Routier, Emilie, Menzies, Alexander M., Eriksson, Hanna, Smith, Myles, Scolyer, Richard A., Hoeller, Christoph, Hansson, Johan, Robert, Caroline, Larkin, James M. G., Long, Georgina V., Blank, Christian U.

“…Abstract only TPS9600 Background: The outcome of high risk stage IIIb and IIIc melanoma patients is poor, with a 5 year overall survival (OS) rate of < 50%…”
Get full text

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma: The OpACIN and OpACIN-neo trials by Versluis, JM, Sikorska, K, Rozeman, EA, Menzies, AM, Eriksson, H, Klop, WMC, Saw, RPM, Van de Wiel, BA, Scolyer, RA, Van Thienen, JV, Mallo, H, Gonzalez, M, Acosta, AT, Grijpink-Ongering, LG, Van der Wal, A, Haanen, JBAG, Van Akkooi, ACJ, Long, GV, Blank, CU

Get full text